The Experts below are selected from a list of 173985 Experts worldwide ranked by ideXlab platform
Maria Angela Bianconcini Trindade - One of the best experts on this subject based on the ideXlab platform.
-
Primary neural leprosy: systematic review Hanseníase neural primária: revisão sistemática
Academia Brasileira de Neurologia (ABNEURO), 2013Co-Authors: José Antonio Garbino, Wilson Marques, Jaison Antonio Barreto, Carlos Otto Heise, Márcia Maria Jardim Rodrigues, Sérgio L. Antunes, Cleverson Teixeira Soares, Marcos Cesar Floriano, José Augusto Nery, Maria Angela Bianconcini TrindadeAbstract:The authors proposed a systematic review on the current concepts of primary neural leprosy by consulting the following online databases: MEDLINE, Lilacs/SciELO, and Embase. Selected studies were classified based on the degree of recommendation and levels of scientific evidence according to the “Oxford Centre for Evidence-based Medicine”. The following aspects were reviewed: cutaneous clinical and laboratorial investigations, i.e. skin clinical exam, smears, and biopsy, and Mitsuda's reaction; neurological investigation (anamnesis, electromyography and nerve biopsy); serological investigation and molecular testing, i.e. serological testing for the detection of the phenolic glycolipid 1 (PGL-I) and the polymerase chain reaction (PCR); and Treatment (Classification criteria for the definition of specific Treatment, steroid Treatment, and cure criteria).Os autores propuseram-se a realizar uma revisão sistemática em conceitos atuais sobre a hanseníase neural primária, consultando as seguintes bases bibliográficas on-line: MEDLINE, Lilacs/SciELO e Embase. Os estudos selecionados foram classificados conforme o grau de recomendação e o nível de evidência científica de acordo com o “Oxford Centre for Evidence-based Medicine”. Os seguintes temas foram revisados: investigações clínica e laboratorial cutâneas, ou seja, exame, esfregaço e biópsia de pele e reação de Mitsuda; investigação neurológica (anamnese, eletroneuromiografia e biópsia de nervo); investigação sorológica e testes moleculares, ou seja, testes sorológicos para detecção de um glicolipídio fenólico e reação de cadeia de polimerase (PCR) e tratamento (critérios de classificação para definição de tratamento específico, tratamento com esteroides e critérios de cura).
-
Primary neural leprosy: systematic review
Academia Brasileira de Neurologia (ABNEURO), 2013Co-Authors: José Antonio Garbino, Wilson Marques, Jaison Antonio Barreto, Carlos Otto Heise, Márcia Maria Jardim Rodrigues, Sérgio L. Antunes, Cleverson Teixeira Soares, Marcos Cesar Floriano, José Augusto Nery, Maria Angela Bianconcini TrindadeAbstract:The authors proposed a systematic review on the current concepts of primary neural leprosy by consulting the following online databases: MEDLINE, Lilacs/SciELO, and Embase. Selected studies were classified based on the degree of recommendation and levels of scientific evidence according to the “Oxford Centre for Evidence-based Medicine”. The following aspects were reviewed: cutaneous clinical and laboratorial investigations, i.e. skin clinical exam, smears, and biopsy, and Mitsuda's reaction; neurological investigation (anamnesis, electromyography and nerve biopsy); serological investigation and molecular testing, i.e. serological testing for the detection of the phenolic glycolipid 1 (PGL-I) and the polymerase chain reaction (PCR); and Treatment (Classification criteria for the definition of specific Treatment, steroid Treatment, and cure criteria)
Claire Louise Hirst - One of the best experts on this subject based on the ideXlab platform.
-
autoimmune disease after alemtuzumab Treatment for multiple sclerosis in a multicenter cohort
Neurology, 2011Co-Authors: Mark D Cossburn, Adrian Pace, Judson Jones, R Ali, Gillian Ingram, K Baker, Claire Louise HirstAbstract:Objective: To define the rate, timing, and clinical risk factors for the development of autoimmune disease (AID) after alemtuzumab Treatment for multiple sclerosis (MS). Methods: We analyzed prospective clinical and serologic data from 248 patients with MS treated with alemtuzumab, with median follow-up of 34.3 months (range 6.7–107.3). Results: Novel AID developed in 22.2%. Thyroid AID was most frequent (15.7%). A range of hematologic, renal, and dermatologic AID were also observed as was asymptomatic development of novel autoantibodies. AID was seen from 2 weeks after initial Treatment and was most frequent 12–18 months after first Treatment. No new cases of AID were identified 60 months or more after initial Treatment and risk of AID was independent of total alemtuzumab dose or interval of dosage. While established risk factors for AID including sex and age had no impact on AID frequency, both family history (odds ratio = 7.31, 95% confidence interval 3.02–17.68) of AID and a personal smoking history (odds ratio = 3.05, 95% confidence interval 1.50–6.19) were predictive of AID expression. Conclusions: Cumulative risk for AID in MS following alemtuzumab is 22.2%, most frequent between 12 and 18 months following first dose and evident for up to 5 years. Individual risk is modified by smoking and family history, which should be incorporated within the counseling process prior to Treatment. Classification of evidence: This study provides Class IV evidence that the risk of AID after alemtuzumab Treatment for MS is time-limited and modified by external factors.
Trindade, Maria Angela Bianconcini - One of the best experts on this subject based on the ideXlab platform.
-
Hanseniase neural primaria: revisao sistematica
Academia Brasileira de Neurologia - ABNEURO, 2013Co-Authors: Garbino, Jose Antonio, Marques Junior Wilson, Barreto, Jaison Antonio, Heise, Carlos Otto, Rodrigues, Marcia Maria Jardim, Antunes, Sergio L., Soares, Cleverson Teixeira, Floriano, Marcos César [unifesp], Nery, Jose Augusto, Trindade, Maria Angela BianconciniAbstract:The authors proposed a systematic review on the current concepts of primary neural leprosy by consulting the following online databases: MEDLINE, Lilacs/SciELO, and Embase. Selected studies were classified based on the degree of recommendation and levels of scientific evidence according to the “Oxford Centre for Evidence-based Medicine”. The following aspects were reviewed: cutaneous clinical and laboratorial investigations, i.e. skin clinical exam, smears, and biopsy, and Mitsuda's reaction; neurological investigation (anamnesis, electromyography and nerve biopsy); serological investigation and molecular testing, i.e. serological testing for the detection of the phenolic glycolipid 1 (PGL-I) and the polymerase chain reaction (PCR); and Treatment (Classification criteria for the definition of specific Treatment, steroid Treatment, and cure criteria).Os autores propuseram-se a realizar uma revisão sistemática em conceitos atuais sobre a hanseníase neural primária, consultando as seguintes bases bibliográficas on-line: MEDLINE, Lilacs/SciELO e Embase. Os estudos selecionados foram classificados conforme o grau de recomendação e o nível de evidência científica de acordo com o “Oxford Centre for Evidence-based Medicine”. Os seguintes temas foram revisados: investigações clínica e laboratorial cutâneas, ou seja, exame, esfregaço e biópsia de pele e reação de Mitsuda; investigação neurológica (anamnese, eletroneuromiografia e biópsia de nervo); investigação sorológica e testes moleculares, ou seja, testes sorológicos para detecção de um glicolipídio fenólico e reação de cadeia de polimerase (PCR) e tratamento (critérios de classificação para definição de tratamento específico, tratamento com esteroides e critérios de cura)
-
Hanseniase neural primaria: revisao sistematica
'FapUNIFESP (SciELO)', 2013Co-Authors: Garbino, Jose Antonio, Marques Junior Wilson, Barreto, Jaison Antonio, Heise, Carlos Otto, Rodrigues, Marcia Maria Jardim, Antunes, Sergio L., Soares, Cleverson Teixeira, Nery, Jose Augusto, Floriano, Marcos César, Trindade, Maria Angela BianconciniAbstract:The authors proposed a systematic review on the current concepts of primary neural leprosy by consulting the following online databases: MEDLINE, Lilacs/SciELO, and Embase. Selected studies were classified based on the degree of recommendation and levels of scientific evidence according to the “Oxford Centre for Evidence-based Medicine”. The following aspects were reviewed: cutaneous clinical and laboratorial investigations, i.e. skin clinical exam, smears, and biopsy, and Mitsuda's reaction; neurological investigation (anamnesis, electromyography and nerve biopsy); serological investigation and molecular testing, i.e. serological testing for the detection of the phenolic glycolipid 1 (PGL-I) and the polymerase chain reaction (PCR); and Treatment (Classification criteria for the definition of specific Treatment, steroid Treatment, and cure criteria).Os autores propuseram-se a realizar uma revisão sistemática em conceitos atuais sobre a hanseníase neural primária, consultando as seguintes bases bibliográficas on-line: MEDLINE, Lilacs/SciELO e Embase. Os estudos selecionados foram classificados conforme o grau de recomendação e o nível de evidência científica de acordo com o “Oxford Centre for Evidence-based Medicine”. Os seguintes temas foram revisados: investigações clínica e laboratorial cutâneas, ou seja, exame, esfregaço e biópsia de pele e reação de Mitsuda; investigação neurológica (anamnese, eletroneuromiografia e biópsia de nervo); investigação sorológica e testes moleculares, ou seja, testes sorológicos para detecção de um glicolipídio fenólico e reação de cadeia de polimerase (PCR) e tratamento (critérios de classificação para definição de tratamento específico, tratamento com esteroides e critérios de cura).Secretaria de Estado de Saude Instituto Lauro de Souza LimaUniversidade de São Paulo (USP) School of Medicine of Ribeirao Preto Department of NeurosciencesUSP Department of Neurology and NeurosurgeryFundacao Oswaldo CruzUniversidade Federal de São Paulo (UNIFESP) Department of DermatologySecretaria de Estado de Saude Instituto de SaudeConselho Federal de Medicina Associacao Medica Brasileira Projeto DiretrizesUNIFESP, Department of DermatologySciEL
José Antonio Garbino - One of the best experts on this subject based on the ideXlab platform.
-
Primary neural leprosy: systematic review Hanseníase neural primária: revisão sistemática
Academia Brasileira de Neurologia (ABNEURO), 2013Co-Authors: José Antonio Garbino, Wilson Marques, Jaison Antonio Barreto, Carlos Otto Heise, Márcia Maria Jardim Rodrigues, Sérgio L. Antunes, Cleverson Teixeira Soares, Marcos Cesar Floriano, José Augusto Nery, Maria Angela Bianconcini TrindadeAbstract:The authors proposed a systematic review on the current concepts of primary neural leprosy by consulting the following online databases: MEDLINE, Lilacs/SciELO, and Embase. Selected studies were classified based on the degree of recommendation and levels of scientific evidence according to the “Oxford Centre for Evidence-based Medicine”. The following aspects were reviewed: cutaneous clinical and laboratorial investigations, i.e. skin clinical exam, smears, and biopsy, and Mitsuda's reaction; neurological investigation (anamnesis, electromyography and nerve biopsy); serological investigation and molecular testing, i.e. serological testing for the detection of the phenolic glycolipid 1 (PGL-I) and the polymerase chain reaction (PCR); and Treatment (Classification criteria for the definition of specific Treatment, steroid Treatment, and cure criteria).Os autores propuseram-se a realizar uma revisão sistemática em conceitos atuais sobre a hanseníase neural primária, consultando as seguintes bases bibliográficas on-line: MEDLINE, Lilacs/SciELO e Embase. Os estudos selecionados foram classificados conforme o grau de recomendação e o nível de evidência científica de acordo com o “Oxford Centre for Evidence-based Medicine”. Os seguintes temas foram revisados: investigações clínica e laboratorial cutâneas, ou seja, exame, esfregaço e biópsia de pele e reação de Mitsuda; investigação neurológica (anamnese, eletroneuromiografia e biópsia de nervo); investigação sorológica e testes moleculares, ou seja, testes sorológicos para detecção de um glicolipídio fenólico e reação de cadeia de polimerase (PCR) e tratamento (critérios de classificação para definição de tratamento específico, tratamento com esteroides e critérios de cura).
-
Primary neural leprosy: systematic review
Academia Brasileira de Neurologia (ABNEURO), 2013Co-Authors: José Antonio Garbino, Wilson Marques, Jaison Antonio Barreto, Carlos Otto Heise, Márcia Maria Jardim Rodrigues, Sérgio L. Antunes, Cleverson Teixeira Soares, Marcos Cesar Floriano, José Augusto Nery, Maria Angela Bianconcini TrindadeAbstract:The authors proposed a systematic review on the current concepts of primary neural leprosy by consulting the following online databases: MEDLINE, Lilacs/SciELO, and Embase. Selected studies were classified based on the degree of recommendation and levels of scientific evidence according to the “Oxford Centre for Evidence-based Medicine”. The following aspects were reviewed: cutaneous clinical and laboratorial investigations, i.e. skin clinical exam, smears, and biopsy, and Mitsuda's reaction; neurological investigation (anamnesis, electromyography and nerve biopsy); serological investigation and molecular testing, i.e. serological testing for the detection of the phenolic glycolipid 1 (PGL-I) and the polymerase chain reaction (PCR); and Treatment (Classification criteria for the definition of specific Treatment, steroid Treatment, and cure criteria)
Ans T Van Der Ploeg - One of the best experts on this subject based on the ideXlab platform.
-
long term benefit of enzyme replacement therapy in pompe disease a 5 year prospective study
Neurology, 2017Co-Authors: Esther Kuperus, Michelle E Kruijshaar, Stephan C A Wens, Juna M De Vries, Marein M Favejee, Jan C Van Der Meijden, Dimitris Rizopoulos, Esther Brusse, Pieter A Van Doorn, Ans T Van Der PloegAbstract:Objective: To determine the effect of enzyme replacement therapy (ERT) after 5 years and to identify predictors for a favorable response because few data are available on the long-term efficacy of ERT in Pompe disease. Methods: We included 102 adult patients with Pompe disease in a nationwide, prospective cohort study. We assessed muscle strength (manual muscle testing with Medical Research Council [MRC] grading, handheld dynamometry [HHD]), muscle function (6-minute walk test, Quick Motor Function Test), daily life activities (Rasch-Built Pompe-Specific Activity [R-PAct] Scale), and pulmonary function (forced vital capacity [FVC] in upright and supine positions, maximum inspiratory and expiratory pressures) at 3- to 6-month intervals before and after the start of ERT. Data were analyzed with linear mixed-effects models for repeated measurements. Results: Median follow-up duration was 6.1 years (range 0.4–7.9 years), of which 5.0 years (range 0.2–7.3 years) were during ERT. Treated patients had better muscle strength (MRC sum score +6.6 percentage points [pp]; HHD sum score +9.6 pp, both p p p p = 0.03). The largest increase was seen during the first 2 to 3 years of Treatment. Response to Treatment was similar between groups regardless of sex, age, or disease duration. Conclusions: Long-term ERT positively affects muscle strength, pulmonary function, and daily life activities in adult patients with Pompe disease, with a peak effect at ≈2 to 3 years of Treatment. Classification of evidence: This study provides Class IV evidence that for patients with Pompe disease, long-term ERT positively affects muscle strength, pulmonary function, and daily life activities.
